Sercan Aksoy

Scopus Author ID Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 31

Top Venues

Cancer research

Breast cancer research and treatment

Cell death & disease

Biomarkers in medicine

Hacettepe Üniversitesi Tıp Fakültesi

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Hacettepe Üniversitesi Tıp Fakültesi Oct 01 1997

Turkey

Faculty Member :: Departmant of Medical Oncology

Publications

Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer research (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer research (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer research (2024)
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Özgür Sahin
Targeting LINC00152 activates cAMP/Ca 2+ /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell death & disease 15 (6) (2024)
Ozge Saatci, Metin Cetin, Meral Uner, Unal Metin Tokat, Ioulia Chatzistamou, Pelin Gulizar Ersan, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Mathew Sajish, Özgür Sahin
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer. Nature communications 14 (1) (2023)
Görkem Yazıcı Şener, Osman Sütçüoğlu, Betül Oğüt, Deniz Can Guven, Altan Kavuncuoglu, Nuriye Ozdemir, Ahmet Özet, Sercan Aksoy, Yeşim Gaye Güler Tezel, Nalan Akyurek, Ozan Yazıcı
Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2023)
Enes Erul, Deniz Can Guven, Yakup Ozbay, Ahmet Y Altunbulak, Alper Kahvecioglu, Fatih Ercan, Muhammed F Yesil, Mete T Ucdal, Mustafa Cengiz, Gözde Yazıcı, Oguz Kuscu, Nilda Sütay Süslü, Ibrahim Gullu, Mehmet Ruhi Onur, Sercan Aksoy
Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma. Biomarkers in medicine (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Judith Balmaña, Peter Andreas Fasching, Fergus J Couch, Suzette Delaloge, Sana Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Goncalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena V Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, A Anton Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, null null
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 204 (2) (2023)
Deniz Can Guven, Taha Koray Sahin, Enes Erul, Ibrahim Yahya Cakir, Enes Ucgul, Hasan Cagri Yildirim, Oktay Halit Aktepe, Mustafa Erman, Saadettin Kilickap, Sercan Aksoy, Suayib Yalcin
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. Journal of clinical medicine 11 (15) (2022)
Pınar Borman, Ayşegül Yaman, Lutfi Dogan, Ayse A Donmez, Esra Gizem Koyuncu, Esra Gizem Koyuncu, Sercan Aksoy, Cihangir Özaslan, Rabiye Akın Işık, Kaniye Üneş
The Comparative Frequency of Breast Cancer-Related Lymphedema Determined by Bioimpedance Spectroscopy and Circumferential Measurements. European journal of breast health 18 (2) (2022)
Filiz Kaya, Ahmet Çagkan Inkaya, Sercan Aksoy, Osman Abbasoğlu, Ali Ihsan Ertenli, Yahya Büyükaşık, Sevtap Arikan-Akdagli, Yakut Akyön Yılmaz, Sibel Ergüven
Investigation of Intestinal Protozoon Prevalence in Immunocompromised Patients at a University Hospital Turkiye parazitolojii dergisi 45 (1) (2021)
Seda Hanife Oğuz, Ugur Unluturk, Sercan Aksoy, Tomris Erbas
Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. Immunotherapy 13 (14) (2021)
Deniz Can Guven, Oktay Halit Aktepe, Hakan Taban, Burak Yasin Aktaş, Gurkan Guner, Hasan C Yildirim, Taha Koray Sahin, Melek S Aksun, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Şuayib Yalçin, Saadettin Kılıçkap
Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors. Biomarkers in medicine 15 (13) (2021)
Abdullah Ağın, Sibel Kocabeyoğlu, Aysun Yucel Gencoglu, Sercan Aksoy, Jale Karakaya, Murat İrkeç
The effects of systemic aromatase inhibitors on meibomian glands and corneal structure. Eye (London, England) (2021)
Emine Baran, Levent Ozcakar, Serap Özgül, Sercan Aksoy, Türkan Akbayrak
Upper limb sensory evaluations and ultrasonographic skin measurements in breast cancer-related lymphedema receiving complex decongestive physiotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 29 (11) (2021)
Deniz Can Guven, Taha Koray Sahin, Sercan Aksoy
The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters. The breast journal 27 (1) (2020)
Ozge Saatci, Aysegul Kaymak, Umar Raza, Pelin Gulizar Ersan, Ozge Akbulut-Caliskan, Carolyn E Banister, Vitali Sikirzhytski, Unal Metin Tokat, Zaliha Gamze Aykut, Suhail A Ansari, Hayriye Tatli Dogan, Mehmet Dogan, Pouria Jandaghi, Aynur Isik, Fatma Gündoğdu, Kemal Kosemehmetoglu, Omer Dizdar, Sercan Aksoy, Aytekin Akyol, Aysegül Uner, Phillip J Buckhaults, Yasser Riazalhosseini, Özgür Sahin
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature communications 11 (1) (2020)
Deniz Can Guven, Taha Koray Sahin, Sercan Aksoy
The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters. The breast journal 26 (12) (2020)
Filiz Kaya, Ahmet Çagkan Inkaya, Ali Ihsan Ertenli, Osman Abbasoğlu, Sercan Aksoy, Yakut Akyön Yılmaz, Sibel Ergüven
The investigation of Strongyloides stercoralis seroprevalence in immunosupressed patients in Turkey Turkish journal of medical sciences 49 (1) (2019)

Sercan Aksoy.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Sercan Aksoy